Genetic variation in the myeloperoxidase gene and cognitive impairment in multiple sclerosis.
There is evidence that multiple sclerosis (MS) may associated with cognitive impairment in 25 to 40% of cases. The gene encoding myeloperoxidase (MPO) is involved in molecular pathways leading to beta-amyloid deposition. We investigated a functional biallelic (G/A) polymorphism in the promoter region (-463) of the MPO gene in 465 patients affected by MS, divided into 204 cognitively normal and 261 impaired. We did not find significant differences in allele or genotype distributions between impaired and preserved MS patients. Our findings suggest that MPO polymorphism is not a risk factor for cognitive impairment in MS.
Manna
I
I
Institute of Neurological Science, National Research Council, Cosenza, Italy. i.manna@isn.cnr.it
Valentino
P
P
La Russa
A
A
Condino
F
F
Nisticò
R
R
Liguori
M
M
Clodomiro
A
A
Andreoli
V
V
Pirritano
D
D
Cittadella
R
R
Quattrone
A
A
D000483:Alleles; D003072:Cognition Disorders / Q000150:complications* / Q000235:genetics / Q000503:physiopathology*; D005787:Gene Frequency; D014644:Genetic Variation / Q000235:genetics*; D005838:Genotype; D006801:Humans; D009103:Multiple Sclerosis / Q000150:complications* / Q000201:enzymology / Q000235:genetics* / Q000503:physiopathology; D009195:Peroxidase / Q000235:genetics*; D011110:Polymorphism, Genetic
D009195:Peroxidase